Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Communication Strategies. Case Studies. Applied Knowledge.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 18 March 2013 | By Alexander Gaffney, RAC
The European Medicines Agency (EMA) has announced that it has simplified the process by which marketing authorization applications (MAAs) are submitted to the agency, reducing the number of applications that marketing authorization holders (MAHs) need to submit during the centralized procedure.
The changes comes just as EU regulators are in the midst of implementing the pharmacovigilance legislation, an EU-wide set of requirements intended to make it easier to track and report post-marketing safety events affecting medicines and patients.
Under the old submission system, MAH's would have to submit multiple copies of a regulatory dossier to various entities.
Under the new submission system, sponsors will be responsible for submitting one copy of their submission to the EMA (Committee for Medicinal Products for Human Use, Committee for Advanced Therapies, and/or the Pharmacovilgilance Risk Assessment Committee) and one copy to each EU member state.
Those applications may be submitted via either the electronic common technical document (eCTD) or a DVD/CD ROM using the relevant submission portals.
In the near future, EMA said it hopes to introduce an electronic submission system common to and accepted by all EU member states, which would have the effect of simplifying the submission process even further.
Tags: PRAC, Centralized Procedure, CAT, Centralised Procedure, application, Latest News, CHMP, submission, EU